Table 1.

Demographic, clinical, and surgery-related characteristics of all patients

	Warfarin	Antiplatelet	Control	Total	p value
Patient	157 (12%)	442 (34%)	693 (54%)	1292 (100%)
Gender
Male	59 (38%)	115 (26%)	159 (23%)	333 (26%)	0.001
Female	98 (62%)	327 (74%)	534 (77%)	959 (74%)
Age, mean ± sd	84.76 ± 6.08	84.09 ± 6.61	83.69 ± 8.15	83.96 ± 7.42	0.3567
ASA score
1/2	0	13 (3%)	69 (10%)	82 (7%)	< 0.001
3	34 (22%)	165 (38%)	350 (51%)	549 (43%)
4/5	120 (78%)	256 (59%)	265 (39%)	641 (50%)
CCI, median (IQR, Q1 to Q3)	6 (5–7)	6 (4–7)	5 (4–6)	5 (4–7)	0.0001
AO/OTA Classification
A1	42 (27%)	93 (21%)	139 (20%)	274 (21%)	0.47
A2	34 (22%)	108 (25%)	164 (24%)	306 (24%)
A3	7 (4%)	43 (10%)	65 (10%)	115 (9%)
B1	20 (13%)	70 (16%)	112 (16%)	202 (16%)
B2	43 (28%)	103 (23%)	168 (24%)	314 (24%)
B3	10 (6%)	22 (5%)	43 (6%)	75 (6%)
Types of surgical procedure
Reconstruction	63 (40%)	178 (40%)	282 (41%)	523 (40%)	0.986
Fixation	94 (60%)	264 (60%)	411 (59%)	769 (60%)
Time to surgery
< 48 h	72 (46%)	277 (63%)	479 (69%)	828 (64%)	< 0.001
> 48 h	85 (54%)	165 (37%)	214 (31%)	464 (36%)
Blood loss (ml)
Median (IQR, Q1 to Q3)	964.04 (446.95–1652.62)	904.105 (454.4–1486.93)	864.3 (394.59–1349.29)	879.02 (419.33–1446.43)	0.0054
0–490 ml	40 (26%)	119 (27%)	241 (35%)	400 (31%)	0.033
491–980 ml	40 (26%)	139 (31%)	197 (28%)	376 (29%)
981–1470 ml	30 (19%)	69 (16%)	96 (14%)	195 (15%)
> 1471 ml	45 (29%)	115 (26%)	157 (23%)	317 (25%)
Mortality
30 days	13 (8%)	14 (3%)	28 (4%)	55 (4%)	0.0484*
180 days	42 (27%)	69 (16%)	100 (14%)	211 (16%)	0.0005*
1 year	61 (39%)	109 (25%)	140 (20%)	310 (24%)	< 0.0001*

Note: *the p values related to mortality at 30 days, 180 days, and 1 year were calculated with the log-rank test